Amendments to the Claims
This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims
Claims 1-20 (Cancelled)

21 (Currently amended). A compound of formula AXB useful in inducing necrosis in vascular tissue of a tumor in a mammal, said compound containing (a) a first moiety, A, which is a cis-stilbene moiety of formula II



II

wherein R1, R2 and R3 are each independently H, optionally substituted alkoxy, optionally substituted alkyl or halogen
R4 is hydrogen or cyano
R5, R6 and R7 are each independently H, hydroxy, optionally substituted alkyl, halogen, amino, alkylamino, dialkylamino, cyano, nitro, carboxyl, alkanoyl, alkoxycarbonyl, alkoxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, di alkylaminocarbonylamino, alkylcarbonylamino, alkylsulphonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl, alkylsulphonylamino, aminosulphonylamino, alkylaminosulphonylamino, dialkylaminosulphonylamino, mercapto, alkylsulphanyl,or alkylsulphinyl,
with the proviso that at least two of R1, R2 and R3 must be optionally substituted alkoxy, and (b) a second moiety, B, which is an inhibitor of nitric oxide synthase said first and second moieties being coupled in the compound by X which is a linker bond or moiety ~~, atom or group X~~ bound to any available valency of B and any available valency of that phenyl ring of Formula II that is substituted by R5, R6 and R7 ~~A~~ such that the compound has an increased activity in inducing necrosis in said vascular tissue as compared with a compound containing said first moiety without the second moiety, wherein X is selected from the group

consisting of an optionally substituted methylene chain and -$(CH2)_m$-Y-$(CH2)_n$ wherein Y is selected from -O-, -S-, -SO_2, NH-, N alkyl, -CO-, -OC(O)-, -NHC(O), -N(alkyl)C(O)-, NNHC())NH-, NalkylC(O)NH-NalkylC(O)Nalkyl, $NHSO_2$, NalkylSO_2-, $NHSO_2NH$, NalkylSO_2NH, NalkylSO_2Nalkyl and -OC(O)O, m is 0 - 3 and n is 0 - 3 or a hydrate or pharmaceutically acceptable salt of the compound.

22 (Canceled)

23 (Previously submitted). The compound according to claim 21, wherein the compound is a hydrate, or a pharmaceutically acceptable salt thereof.

24 (cancelled). .

25 (cancelled)

26 (Previously submitted) The compound according to claim 21, in which the second moiety is selected from the group consisting of an amino acid inhibitor of nitric oxide synthase, a thiocitrulline derivative, an S-alkylisothiourea derivative and a 2-aminopyridine derivative.

Claim 27 (Previously submitted) The compound according to claim 21, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2)p-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio, or a group -NHCH(CO_2R10)-(CH_2)p-NHC(NH)Z and R10 is hydrogen or alkyl.

Claim 28 (Previously submitted) The compound according to claim 21, wherein the second moiety is a group -C(O)CH(NH_2)-CH_2p-NHC(S)NH_2 or a group -NHCH(CO_2R10)-(CH_2)p-NHC(S)NH_2.

Claim 29 (Previously submitted) The compound according to claim 21, wherein the second moiety is -(CH_2)p-SC(NH)NH_2.

Claim 30 (Previously submitted) The compound according to claim 21, wherein the second moiety is 4-methyl-2-pyridinylamino.

Claim 31 (Previously submitted) The compound according to claim 21, wherein the compound is



wherein R8 is alkyl, amino, hydroxy, alkoxy or halogen.

Claim 32 (Previously submitted) The compound according to claim 31, wherein X is -O- or -NH- and B is a group -C(O)CH(NH_2)-(CH_2)p-NHC(NH)Z, wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio or a group -NHCH(CO_2R10)-(CH_2)p-NHC(NH)Z and wherein R10 is hydrogen or alkyl.

Claim 33 (Previously submitted) The compound according to claim 32, wherein the compound is



wherein
R9 is alkyl, alkoxy or halogen
X_1 is O or NH
B_1 is a group -C(O)CH(NH_2)$_p$-NHC(NH)Z wherein p is 1-5 and Z is alkyl, alkylamino, dialkylamino, nitroamino, hydrazino or alkylthio.

34 (Previously submitted) The compound according to claim 21, wherein the compound is selected from the group consisting of
(Z)-1-(4-methoxy-3-N^G-nitroarginyloxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene
(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine methyl ester;
(Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine;

and
(Z)-N-[2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenoxycarbonyl]N^G- nitroarginine methyl ester.

35 (Previously submitted) The compound according to claim 21, wherein the first and second moieties are coupled through a linker bond.

36 (previously submitted). A method for inducing necrosis in vasculature of a tumor in a mammal, comprising administering to the ~~animal~~ mammal the compound of claim 34 in an amount effective for said inducing.

37 (previously submitted). A method for inducing necrosis in vasculature of a tumor in a mammal, comprising administering to the ~~animal~~ mammal the compound of claim 21 in an amount effective for said inducing.

38 (previously submitted). A method for inducing necrosis in vasculature of a tumor in a mammal ~~an animal~~, comprising administering to the mammal the compound of claim 24 in an amount effective for said inducing.

39 (Previously submitted). A method for inducing necrosis in vasculature of a tumor in a mammal, comprising administering to the mammal the compound of claim 27 in an amount effective for said inducing.

40 (currently amended). A method for inducing necrosis in vasculature of a tumor in a mammal, comprising administering to the ~~animal~~ mammal the compound of claim 31 in an amount effective for said inducing.